PF-07104091 free base · Synonyms: PF 07104091 · PF07104091

PF-07104091 is an orally bioavailable inhibitor of cyclin-dependent kinase 2.

For research use only. Not for human or veterinary use.

Target CDK GSK-3

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS

PF-07104091 structure

CAS No.: 2460249-19-6

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 650.00	BP-02225-250mg	In stock	Get quote
500 mg	USD 1,050.00	BP-02225-500mg	In stock	Get quote
1 g	USD 1,750.00	BP-02225-1g	In stock	Get quote
5 g	Inquire	BP-02225-5g	In stock	Inquire
10 g	Inquire	BP-02225-10g	In stock	Inquire

Custom Size Bulk Inquiry

Description

PF-07104091 is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2).

Identifiers

SMILES: O=C(C1=CC(COC)=NN1C)NC2=NNC([C@](CC3)([H])C[C@@H]3OC(NC(C)C)=O)=C2
InChIKey: MTNBRBDFNSGQKB-GXTWGEPZSA-N

Specifications

MW (average): 404.4634
Formula: C₁₉H₂₈N₆O₄
CAS No.: 2460249-19-6
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO、Ethanol

In vitro: DMSO: Sparingly soluble: 1-10 mg/ml Ethanol: Sparingly soluble: 1-10 mg/ml

Documents

References

[1]. Chen Y, Cai Q, Pan C, et al. CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses. Cancer Immunol Res. 2022;10(4):525-539. doi:10.1158/2326-6066.CIR-21-0806

[2]. Douglas Carl BEHENNA, et al. Cdk2 inhibitors. WO2020157652A2.

Same target

Search CDK

Same research area

Search Cancer